| Literature DB >> 28662713 |
Taku Mochizuki1, Takashi Kawahara2,3, Daiji Takamoto1, Kazuhide Makiyama4, Yusuke Hattori1, Jun-Ichi Teranishi1, Yasuhide Miyoshi1, Yasushi Yumura1, Masahiro Yao4, Hiroji Uemura1.
Abstract
BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR) is reported as a biomarker for some solid malignant diseases. Thus far, however, no reports of the relationship between the NLR and adrenal tumors have been published. We analyzed the utility of the preoperative NLR as a biomarker for predicting the prognosis or diagnosis of malignant disease.Entities:
Keywords: Adrenal tumor; Adrenocortical carcinoma; Biomarker; Neutrophil-to-lymphocyte ratio
Mesh:
Year: 2017 PMID: 28662713 PMCID: PMC5490233 DOI: 10.1186/s12894-017-0240-4
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Each adrenal tumor’s characteristics
| adrenocortical adenoma | pheochromocytoma | adrenocortical carcinoma | malignant lymphoma | |
|---|---|---|---|---|
| n | 33 | 13 | 9 | 4 |
| Sex (male: female) | 10: 23 | 6: 7 | 1: 8 | 3: 1 |
| Age (median) | 50 | 57 | 64 | 70 |
| Maximum tumor diameter (mm) (mean) | 22 | 40 | 100 | 91 |
| NLR (median) | 2.84 | 2.03 | 6.02 | 3.30 |
Adrenocortical carcinoma patients’ characteristics
| No | Age | Sex | Maximum diameter (mm) | Endocrine activity | Capsule invasion | Clinical stage | Chemotherapy | Outcome | Observation period (months) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 85 | F | 96 | − | NA | StageIV | − | dead | 1 |
| 2 | 19 | F | 125 | + | + | StageIII | + | dead | 5 |
| 3 | 64 | F | 72 | − | NA | StageIV | + | dead | 42 |
| 4 | 62 | M | 100 | − | + | StageIV | + | dead | 9 |
| 5 | 64 | F | 105 | − | NA | StageIV | + | dead | 2 |
| 6 | 66 | F | 70 | − | + | StageIV | + | dead | 30 |
| 7 | 42 | F | 108 | − | − | StageIV | + | dead | 17 |
| 8 | 34 | F | 125 | − | − | StageIV | − | dead | 17 |
| 9 | 72 | F | 18 | − | + | StageI | − | alive | 27 |
Fig. 1Comparison NLR of malignant adrenal tumor to NLR of non-malignant adrenal tumor
Fig. 2Comparison NLR of adrenocortical carcinoma, pheochromocytoma, adrenal malignant lymphoma and adrenal adenoma
Fig. 3Receiver operator characteristics curve to detect cut off point of NLR to detect malignant disease or not (area under ROC: 0.668)
The results of the multivariate analysis
|
| HR | 95% CI | |
|---|---|---|---|
| Gender (male) | 0.332 | 0.353 | 0.043–2.892 |
| Age (≥57) | 0.099 | 5.720 | 0.719–45.504 |
| NLR (≥3.15) | 0.037 | 8.990 | 1.142–70.547 |
| Size (≥40 mm) | <0.001 | 112.400 | 7.39–1710.5 |
Fig. 4Overall survival of adrenocortical carcinoma according to the NLR